CyDex, Inc. Announces Captisol Technology Used in Injection Formulation of Veterinary Anti-Emetic Cerenia(R) (Maropitant) Recently Approved for Marketing in Europe
4/10/2007 12:32:50 PM
LENEXA, Kan.--(BUSINESS WIRE)--CyDex, Inc., a specialty pharmaceutical company developing improved products through innovative drug delivery, today announced that a subcutaneous injection formulation of the veterinary anti-emetic medication Cerenia® (maropitant) from Pfizer Limited contains CyDex’s Captisol®-enabling technology.
comments powered by